Therapy of Clostridium difficile infection: perspectives on a changing paradigm

Bibliography

• Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Inf Control Hosp Epidemiol 2011;34:387-90
   Google Scholar
• Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010;51:1306-13
   PubMed Web of Science ®Google Scholar
• Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011;53(1):42-8
   PubMed Web of Science ®Google Scholar
• Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011;53(5):440-7
   PubMed Web of Science ®Google Scholar
• Pant C, Deshpande A, Anderson MP, et al. Clostridium difficile infection is associated with poor outcomes in end-stage renal disease. J Investig Med 2012;60(2):529-32
   PubMed Web of Science ®Google Scholar
• MacDonald LC, Lessa F, Sievert D, et al. Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012;61(9):157-62
   PubMedGoogle Scholar
• Neofytos D, Kobayashi K, Alonso CD, et al. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients. Transpl Infect Dis 2013;15(2):134-41
   PubMed Web of Science ®Google Scholar
• Goldstein EJC. Citron DM, Sears P, et al. Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of Clostridium difficile infection. Antimicrob Agents Chemother 2011;55:5194-9
   PubMed Web of Science ®Google Scholar
• Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI Strain Clin Infect Dis 2012;55(3):351-7
   PubMed Web of Science ®Google Scholar
• Brecher SM, Novak-Weekley SM, Nagy E. Laboratory diagnosis of Clostridium difficile infections: a practical guide for clinicians: there is light at the end of the Colon. Clin Infect Dis 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55
   PubMed Web of Science ®Google Scholar
• Pepin J, Alary ME, Valiquette L. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec. Canada. Clin Infect Dis 2005;40:1591-7
   PubMed Web of Science ®Google Scholar
• Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012;55(Suppl 2):S77-87
   PubMed Web of Science ®Google Scholar
• Walker AS, Eyre DW, Wyllie DH, et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013;56:1589-600
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-31
   PubMed Web of Science ®Google Scholar
• Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12(4):281-9
   PubMed Web of Science ®Google Scholar
• Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983;2(8358):1043-6
   PubMed Web of Science ®Google Scholar
• Baines SD, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62(5):1046-52
   PubMed Web of Science ®Google Scholar
• Lynch T, Chong P, Zhang J, et al. Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLoS One 2013;8(1):e53757
   PubMed Web of Science ®Google Scholar
• Martin H, Willey B, Low DE, et al. Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol 2008;46(9):2999-3004
   PubMed Web of Science ®Google Scholar
• Peláez T, Alcalá L, Blanco JL, et al. Characterization of swine isolates of Clostridium difficile in Spain: a potential source of epidemic multidrug resistant strains? Anaerobe 2013;22:45-9
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Sanders IM, et al. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. J Antimicrob Chemother 2013;68(6):1305-11
   PubMed Web of Science ®Google Scholar
• Weinisch JM, Schmidt D, Kuo H-W, et al. Prospective observational study comparing three different treatment regimens in patients with Clostridium difficile infections Antimicrob Agents Chemother. 2012;56:1974-8
   Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-7
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012;55(Suppl 2):S143-8
   PubMedGoogle Scholar
• Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40(11):1586-90
   PubMed Web of Science ®Google Scholar
• Fisher DA, Maple JT, Ben-Menachem T, et al. ASGE Standards of Practice Committee. Complications of colonoscopy. Gastrointest Endosc 2011;74(4):745-52
   PubMed Web of Science ®Google Scholar
• Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011;254:423-7
   PubMed Web of Science ®Google Scholar
• Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis 2012;55(Suppl 2):S127-31
   PubMedGoogle Scholar
• Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009;53(1):261-3
   PubMed Web of Science ®Google Scholar
• Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012;55(Suppl 2):S155-42
   Google Scholar
• Sears P, Crook DW, Louie TJ, et al. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 2012;55(Suppl 2):S11-S120
   Google Scholar
• Goldstein EJ, Citron DM, Sears P, et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 2011;55:5194-9
   PubMed Web of Science ®Google Scholar
• Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009;53(1):261-3
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-31
   PubMed Web of Science ®Google Scholar
• Johnson S, Gerding DN. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis 2013;56(2):309-10
   PubMed Web of Science ®Google Scholar
• Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection-focus on fidaxomicin. Inf Drug Resistance 2013;6:41-53
   PubMedGoogle Scholar
• Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51(8):2716-19
   PubMed Web of Science ®Google Scholar
• Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43(4):518-24
   PubMed Web of Science ®Google Scholar
• Jump RL, Li Y, Pultz MJ, et al. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 2011;55(2):546-9
   PubMed Web of Science ®Google Scholar
• Baines SD, Saxton K, Freeman J, et al. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006;58(5):1062-5
   PubMed Web of Science ®Google Scholar
• Kothary V, Scherl EJ, Bosworth B, et al. Rifaxamin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaxamin use, mutations in rpoB and activity of Phe-Arg-B-naphthylamise-inhibitable efflux pumps. Antimicob Agents Chemother 2013;57:811-17
   PubMed Web of Science ®Google Scholar
• Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009;48:425
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-6
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Patel U, et al. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009;15:290-1
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44(6):846-8
   PubMed Web of Science ®Google Scholar
• Rubin DT, Sohi S, Glathar M, et al. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract 2011;2011:106978
   PubMed Web of Science ®Google Scholar
• Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011;66(12):2850-5
   PubMed Web of Science ®Google Scholar
• Basu PP, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 2010;3(4):221-5
   PubMedGoogle Scholar
• Lao D 2nd, Chiang T, Gomez E. Refractory Clostridium difficile infection successfully treated with tigecycline, Rifaximin, and Vancomycin. Case Rep Med 2012;2012:702910
   PubMedGoogle Scholar
• Neff GW, Jones M, Jonas M, et al. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. J Clin Gastroenterol 2013;47(2):188-92
   PubMed Web of Science ®Google Scholar
• Rossignol JF. Nitazoxanide, a new broad spectrum antibacterial antiparasiticidal drug: pre-clinical pharmacology. J Trop Med 1994;3:1-6
   Google Scholar
• Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007:51:2716-19
   Google Scholar
• McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000;44(9):2254-8
   PubMed Web of Science ®Google Scholar
• Rafiullah F, Kanwal S, Majeed UM, et al. Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. BMJ Case Rep. 2011; pii: bCR0420114123. doi: 10.1136/bCR.04.2011.4123
   Google Scholar
• Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43(4):421-7.
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48(4):e41-6
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59(4):705-10
   PubMed Web of Science ®Google Scholar
• Lawley TD, Clare S, Walker AW, et al. Targeted restoration of the intestinal microbiota with as simple, defined bacteriotherapy resolves relapsing C. difficile disease in mice. PLoS Pathog 2012;8:e1002995
   PubMed Web of Science ®Google Scholar
• Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854-9
   PubMed Web of Science ®Google Scholar
• Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53(10):994-1002
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5):407-15
   PubMed Web of Science ®Google Scholar
• Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012;46(2):145-9
   PubMed Web of Science ®Google Scholar
• Nakamura S, Nakashio S, Mikawa M, et al. Antimicrobial susceptibility of Clostridium difficile from different sources. Microbiol Immunol 1982;26(1):25-30
   PubMed Web of Science ®Google Scholar
• Nord CE, Olsson-Liljequist B. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983. Scand J Infect Dis Suppl 1984;43:44-9
   PubMedGoogle Scholar
• Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004;54(1):211-16
   PubMed Web of Science ®Google Scholar
• Wenisch C, Parschalk B, Hasenhündl M. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22(5):813-18
   PubMed Web of Science ®Google Scholar
• Huang H, Fang H, Weintraub A, et al. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect 2009;15(12):1170-3
   PubMed Web of Science ®Google Scholar
• Norén T, Akerlund T, Wullt M, et al. Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile. Antimicrob Agents Chemother 2007;51(5):1840-3
   PubMed Web of Science ®Google Scholar
• Norén T, Wullt M, Akerlund T, et al. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 50(9):3028-32
   PubMed Web of Science ®Google Scholar
• LaMarche MJ, Leeds JA, Amaral A, et al. Discovery of LFF571: an investigational agent for Clostridium difficile infection. Med Chem 2012;55:2376-87
   Web of Science ®Google Scholar
• Zuurmond AM, Martien de Graaf J, Olsthoorn-Tieleman LN, et al. GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J Mol Biol 2000;304(5):995-1005
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Merriam CV, et al. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2012;56(5):2493-503
   PubMed Web of Science ®Google Scholar
• Trzasko A, Leeds JA, Praestgaard J, et al. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother 2012;56:4459-62
   PubMed Web of Science ®Google Scholar
• Ting LS, Praestgaard J, Grunenberg N, et al. A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob Agents Chemother 2012;56(11):5946-51
   PubMed Web of Science ®Google Scholar
• Leeds JA, Sachdeva M, Mullin S, et al. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother 2012;56:4463-5
   PubMed Web of Science ®Google Scholar
• Mascio CT, Mortin LI, Howland KT, et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 2012;56(10):5023-30
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Merriam CV, et al. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 2012;56(3):1613-15
   PubMed Web of Science ®Google Scholar
• Chesnel L, Sambol S, Gerding D, et al. Treatment of CDAD with oral CB-183 315: time to recurrence, relapse and re-infection rates compared with vancomycin. Clin Microbiol Infect 2012;18(Suppl 3):380
   Google Scholar
• Goldstein EJC, Citron DM, Tyrrell KL, Merriam CV. Comparative in-vitro activity of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and-negative aerobic and anaerobic gut flora isolates. Antimicrob Agents Chemother 2013; Epub ahead of print
   Google Scholar
• Rashid M-U, Lozano HM, Weintraub A, Nord CE. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm. Sweden. Anaerobe 2013;20:32-5
   PubMed Web of Science ®Google Scholar
• Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infections. J Infect Dis 2013;207(10):1498-504
   PubMed Web of Science ®Google Scholar
• O'Connor R, Baines SD, Freeman J, Wilcox MH. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. J Antimicrob Chemother 2008;62(4):762-5
   PubMed Web of Science ®Google Scholar
• Baines SD, O'Connor R, Saxton K, et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008;62(5):1078-85
   PubMed Web of Science ®Google Scholar
• Chilton CH, Freeman J, Crowther GS, et al. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2012;67(10):2434-7
   PubMed Web of Science ®Google Scholar
• Fekety R, Silva J, Kauffman C, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989;86(1):15-19
   PubMed Web of Science ®Google Scholar
• Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48(12):1732-5
   PubMed Web of Science ®Google Scholar
• Lu CL, Liu CY, Liao CH, et al. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 2010;35:311-12
   PubMed Web of Science ®Google Scholar
• Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010;38:755-8
   PubMed Web of Science ®Google Scholar
• Cheong EY, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust 2011;194:374-5
   PubMed Web of Science ®Google Scholar